NASDAQ:CBUS

Cibus (CBUS) Stock Price, News & Analysis

$17.74
-0.11 (-0.62%)
(As of 05/10/2024 08:54 PM ET)
Today's Range
$17.40
$18.20
50-Day Range
$14.90
$22.82
52-Week Range
$8.90
$38.85
Volume
50,500 shs
Average Volume
61,022 shs
Market Capitalization
$383.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Cibus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.9% Upside
$25.00 Price Target
Short Interest
Bearish
3.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.06mentions of Cibus in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.99) to ($2.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Consumer Staples Sector

117th out of 137 stocks

Agricultural Chemicals Industry

9th out of 9 stocks

CBUS stock logo

About Cibus Stock (NASDAQ:CBUS)

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

CBUS Stock Price History

CBUS Stock News Headlines

Cibus (NASDAQ:CBUS) Stock Rating Reaffirmed by HC Wainwright
Obama’s Forever Term [exposed]
America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.
Cibus Reports Q1 Loss, Tops Revenue Estimates
Cibus Inc Ordinary Shares - Class A CBUS
Obama’s Forever Term [exposed]
America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.
Cibus’s Market Potential and Advancements Justify Buy Rating
CBUS May 2024 30.000 call
CBUS Sep 2024 12.500 put
EU Greenlights Cibus To Enter Its Massive Market
See More Headlines
Receive CBUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cibus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/13/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CBUS
Fax
N/A
Employees
183
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+40.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-267,640,000.00
Net Margins
-12,313.28%
Pretax Margin
-18,582.44%

Debt

Sales & Book Value

Annual Sales
$1.82 million
Cash Flow
$7.75 per share
Book Value
$12.38 per share

Miscellaneous

Free Float
10,941,000
Market Cap
$383.54 million
Optionable
Optionable
Beta
1.99
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Rory Balfour Riggs M.B.A. (Age 71)
    Co-Founder, CEO & Chairman
  • Dr. Peter Beetham B.Sc. (Age 61)
    Ph.D., Co-Founder, President, COO & Director
  • Dr. Greg Gocal Ph.D. (Age 55)
    Co-Founder, Chief Scientific Officer & Executive VP
  • Dr. Wade Hampton King (Age 66)
    Chief Financial Officer
  • Mr. Steve Berreth
    General Counsel & Corporate Secretary
  • Ms. Rosa Cheuk Kim J.D.
    Senior Vice President of Legal
  • Dr. James Radtke Ph.D.
    Senior Vice President of Product Development
  • Mr. Tony Moran
    Senior Vice President of International Development
  • Norm Sissons
    Senior Vice President of Seed & Traits
  • Ms. Noel Sauer Ph.D.
    Senior Vice President of Research

CBUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Cibus stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cibus in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CBUS shares.
View CBUS analyst ratings
or view top-rated stocks.

What is Cibus' stock price target for 2024?

1 brokerages have issued 12 month price targets for Cibus' shares. Their CBUS share price targets range from $25.00 to $25.00. On average, they predict the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts price targets for CBUS
or view top-rated stocks among Wall Street analysts.

How have CBUS shares performed in 2024?

Cibus' stock was trading at $19.64 at the beginning of the year. Since then, CBUS stock has decreased by 9.7% and is now trading at $17.74.
View the best growth stocks for 2024 here
.

When is Cibus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our CBUS earnings forecast
.

How were Cibus' earnings last quarter?

Cibus, Inc. (NASDAQ:CBUS) released its quarterly earnings results on Thursday, May, 9th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by $0.11. The firm earned $0.55 million during the quarter, compared to analysts' expectations of $0.40 million. Cibus had a negative trailing twelve-month return on equity of 21.42% and a negative net margin of 12,313.28%. During the same period in the prior year, the company posted ($5.45) earnings per share.

When did Cibus IPO?

Cibus (CBUS) raised $100 million in an IPO on Thursday, February 14th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO.

Who are Cibus' major shareholders?

Cibus' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.34%).
View institutional ownership trends
.

How do I buy shares of Cibus?

Shares of CBUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CBUS) was last updated on 5/13/2024 by MarketBeat.com Staff

From Our Partners